RICHMOND, Calif., Aug. 9, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO) today reported its second quarter 2017 financial results and recent accomplishments.
"In the second quarter we strengthened our balance sheet in order to position Sangamo for the rapid development of our therapeutic pipeline," said Dr. Sandy Macrae, CEO of Sangamo.
"In the second quarter we strengthened our balance sheet in order to position Sangamo for the rapid development of our therapeutic pipeline," said Dr. Sandy Macrae, CEO of Sangamo.
